Celltrion

068270.KO

125.93 USD

1.20

+0.96%

Overview

Last close

125.93 usd

Market cap

27.10B usd

52 week high

167.56 usd

52 week low

92.59 usd

Target price

165.64 usd

Valuation

P/E

N/A

Forward P/E

30.3951

Price/Sales

14.5178

Price/Book Value

2.2895

Enterprise Value

27.69B usd

EV/Revenue

13.798

EV/EBITDA

51.9874

Key financials

Revenue TTM

1.86B usd

Gross Profit TTM

827.43M usd

EBITDA TTM

538.10M usd

Earnings per Share

N/A usd

Dividend

0.35 usd

Total assets

14.57B usd

Net debt

N/A usd

About

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.